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Five genetically distinct human rotavirus (HRV) gene 4 groups have been described on the basis ofcomparative
nucleotide sequencing and the predicted amino acid sequences, and at least four of them represent distinct VP4
antigenic types. To identify each gene 4 type and investigate its distribution in HRV isolates from patients with
diarrhea, we developed a polymerase chain reaction (PCR) typing method using sequence information available
for four genetically distinct gene 4 types. Rotavirus double-stranded RNAs (dsRNAs) isolated from stool samples
were first reverse transcribed and amplified by PCR by using two oligonucleotide primers that correspond to
regions that are highly conserved among all known HRV gene 4 types. The 876-bp dsDNA products were then
reamplified by PCR in the presence of a cocktail containing one conserved plus-sense primer and four
type-specific minus-sense primers (selected from the hypervariable region of gene 4), resulting in products of345,
483, 267, and 391 bp corresponding to gene 4 types 1, 2, 3, and 4, respectively. This method reliably identified
the gene 4 types of 16 well-characterized HRV isolates. Our results were independently confirmed for all 16
strains by reverse transcription and PCR amplification of HRV dsRNA in the presence of alternate type-specific
primer pairs. For direct gene 4 typing of HRV in stool samples, we developed a method to extract rotavirus
dsRNA from stool specimens by using glass powder. Our results suggest that gene 4 typing will be useful in
providing more a complete characterization of HRV strains of epidemiologic or vaccine-related interest.
The importance of group A human rotaviruses (HRVs) in
diarrheal illnesses of infants and young children has resulted
in efforts to develop a vaccine (7) and to characterize the
antigens involved in immunity. At least seven serotypes of
HRV have been described on the basis of cross-neutraliza-
tion studies with hyperimmune sera containing neutralizing
antibodies to both the VP7 and VP4 polypeptides (15, 30).
Genetic and molecular experiments and studies with neutral-
izing, serotype-specific monoclonal antibodies (MAbs) have
identified VP7 as a major type-specific neutralization protein
(15). The availability of MAbs that specifically bind the VP7
polypeptides of HRV serotypes 1 to 4 led to the development
of enzyme immunoassays (EIAs) for the rapid serotyping of
HRV in stool samples (31). As a result, antigenic diversity in
the VP7 polypeptide of HRV is well defined. These methods
have been used in epidemiologic surveys of circulating
HRVs to demonstrate that serotypes 1 to 4 are found
worldwide, whereas the distribution serotypes 8 and 9 and
the newly described serotype 12 have not been studied
extensively (15, 30, 32).
Antigenic diversity within the VP4 neutralization antigen
has not been clearly defined. The observation that rotavi-
ruses isolated from humans or animals may possess dual
serotype specificities and that the second specificity resides
on VP4 suggests that a complete antigenic characterization
of rotaviruses should include VP4 as well as VP7 (13, 25).
Through comparative nucleotide sequencing, five genetically
distinct gene 4 types have been identified among HRV
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strains on the basis of sequence and predicted amino acid
conservation in strains that possess the same type and
extensive diversity in strains with a different type (9). Strains
that possess one or the other of the gene 4 types (referred to
as P types 1 to 5) have been designated as belonging to VP4
genetic groups 1 to 5 (9). P type 1 is present in symptomatic
strains of VP7 serotypes 1, 3, 4, and 9 (designated VP4
genetic group 1), P type 2 is present in members of VP7
serotype 2 (genetic group 2), P type 3 is present in strains
with VP7 serotype 1 to 4 specificities (so far isolated only
from newborn infants excreting rotavirus asymptomatically)
(genetic group 3), P type 4 is present in the VP7 serotype 1
strain K8 (genetic group 4) (29), and P type 5 is present in the
VP7 serotype 8 strain 69M (genetic group 5) (27). Recently,
experimental evidence that members of VP4 genetic groups
1 to 4 can be divided into three antigenic groups, tentatively
designated serotypes, and one subtype has been presented.
The evidence was obtained on the basis of cross-neutraliza-
tion tests with antisera to baculovirus-expressed VP4 poly-
peptides of prototype strains KU (group 1), DS1 (group 2),
1076 (group 3), and K8 (group 4) (10). Furthermore, all
members of the same genetic group fell within the same
antigenic group. Taken together, these results suggest that
methods for identifying VP4 genetic groups at the nucleic
acid level would be a valid proxy method to assess the
diversity of gene 4 in circulating strains of HRV.
Recently, a hybridization method for identifying VP4
genetic groups has been described (17). In the present study
we report the development of a polymerase chain reaction
(PCR) method to identify (or type) gene 4 types 1 to 4 and
demonstrate that 16 prototype strains from known VP4
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genetic groups could reliably be identified. Furthermore, to
increase the sensitivity of PCR for clinical specimens, we
developed a method for direct extraction of rotavirus dou-
ble-stranded RNA (dsRNA) from stool specimens using
glass powder. This method, in conjunction with gene 4 typing,
can be used to study the molecular epidemiology of HRV
gene 4 in nature. Along with the EIA (31), hybridization (6),
and PCR (12) methods for identifying VP7 serotypes, gene 4
typing permits a more complete characterization of neutrali-
zation genes and antigens of epidemiologically important
rotaviruses and may facilitate the discovery of new gene 4
types.
MATERIALS AND METHODS
Cells. MA104 cells were obtained from the Biologic Prod-
ucts Branch of the Centers for Disease Control and were
grown in medium 199 (GIBCO, Long Island, N.Y.) with 5%
fetal bovine serum at 37°C in a water-jacketed incubator with
5% CO2 or in a 37°C room on a roller bottle apparatus.
Viruses. HRV strains were grown in MA104 cells and were
purified by established methods (20). Virus particle and
nucleic acid concentrations were estimated from the rela-
tionship that purified virions suspended at 185 ,g of viral
protein per ml contain a particle concentration of 2.1 x
1012/ml and a dsRNA concentration of 45 ptg/ml (23). Viral
protein was estimated by using the Bio-Rad assay (Rich-
mond, Calif.).
Stool samples were obtained from collections previously
sent to the Centers for Disease Control for analysis. Samples
from the United States were from patients with gastroenteri-
tis and were submitted by members of the Rotavirus Study
Group (19). Samples from Mexico and Costa Rica were also
from patients with gastroenteritis or were from asympto-
matic infants who secreted rotavirus and were submitted by
G. Ruiz-Palacios and L. Mata for a collaborative serotyping
project (32). Venezuelan samples were from asymptomatic
newborn infants (in neonatal hospital wards) who excreted
rotavirus (17). Samples for gene 4 typing were selected
randomly from samples with known (G, VP7) serotypes,
without regard to virus particle number.
Enzymes. Super-reverse transcriptase was from Molecular
Genetics Resources (Tampa, Fla.), Taq and Amplitaq poly-
merases were from Perkin-Elmer Cetus (Norwalk, Conn.),
and proteinase K was from Boehringer Mannheim (Indianap-
olis, Ind.).
Oligonucleotide primers. Primers were synthesized in the
CDC Biotechnology Core Facility, Centers for Disease
Control (Brian Holloway), and were used without purifica-
tion. One pair of primers, con 3 and con 2, made against the
KU virus gene 4 sequence (accession number M21014) (Fig.
1) was chosen for the first amplification because the primers
correspond to regions that are highly conserved among HRV
strains from VP4 genetic groups 1 to 4, as determined by best
fit analysis with the University of Wisconsin Genetics Com-
puter Group sequence analysis program (3) (using sequences
found in the GenEMBL data bank). Gene 4 sequences for
HRV strains 1076, K8 (30) (accession number not available),
RV5 (accession number M32559), and 69M (accession num-
ber M60600) were loaded into a VAX computer directory for
use with the Genetics Computer Group program. The nucle-
otide sequence of the gene 4 of strain 1076 was provided by
one of the authors (8). The typing primers were selected
from the regions (the 5'-terminal 30%) of gene 4 known to be
highly divergent between strains in different genetic groups
and (when data were available) highly conserved in strains
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FIG. 1. HRV gene 4. The schematic shows the positions and
directions of amplification relative to those for the plus (mRNA)-
sense genomic strand for the consensus primers con 3 and con 2 and
for the gene 4 type-specific primers iT-1 to 4T-1. The sizes of the
expected products of amplification from con 3, con 2 (first amplifi-
cation), and con 3 plus iT-1 through 4T-1 (second amplification,
gene 4 typing PCR) are also shown.
from the same group (9). Five specific typing primers were
prepared for gene 4 sequences of KU (primer iT-1, VP4
genetic group 1), RV5 (primer 2T-1, group 2), 1076 (primer
3T-1, group 3), K8 (primer 4T-1, group 4), and 69M (primer
5T-1, group 5) (primer 5T-1 was selected after the sequence
of the strain 69M gene 4 was published and does not appear
in Fig. 1). The nucleotide (nt) positions and sequences of
these primers (5' to 3') were as follows: con 3 (nt 11 to 32),
TGGCTTCGCCATTTLATAGACA; con 2 (nt 868 to 887),
ATTTCGGACCAT'lTATAACC; iT-i (nt 339 to 356), TCT
ACTTGGATAACGTGC; 2T-1 (nt 474 to 494), CTATTGTT
AGAGGTTAGAGTC; 3T-1 (nt 259 to 278), TGTTGATTAG
TTGGATTCAA, 4T-1 (nt 385 to 402), TGAGACATGCAA
TTGGAC; 5T-1 (nt 575 to 594), ATCATAGTTAGTAG
TCGG.
A second set of genetic group-specific primer pairs was
selected to confirm the results obtained with the typing
primers. Their nucleotide positions on gene 4, polarities
(plus or minus sense), and sequences (5' to 3') were as
follows: iC-1 (nt 314 to 331, plus sense), GGACTGCAGTA
GTTGCTA; 1C-2 (nt 474 to 494, minus sense), TTAGTAT
CAGAAGTTAGTGTA; 2C-1 (nt 1324 to 1344, plus sense),
ATACGAACACGTACAATAAAC; 2C-2 (nt 1809 to 1828,
minus sense), CATCATTIACTGAGTCAGTT; 3C-1 (nt 261
to 278, plus sense), GAATCCAACTAATCAACA; 3C-2 (nt
446 to 467, minus sense), TGTTGAAATTCGGCACTAACA;
3C-3 (nt 288 to 312, plus sense), AGAGGGTACCAA
TAAAACTGATAT; 3C-4 (nt 589 to 606, minus sense), TGC
AGTTTCTACTl'CAGA; 4C-1 (nt 223 to 242, plus sense),
ACCTCACTCAACTTAGT; and 4C-2 (nt 464 to 484, minus
sense), ATAATGTTGAATATTGAGTGT.
RNA extraction. Rotavirus dsRNA was extracted from
lysates of rotavirus-infected MA104 cells with phenol-chlo-
roform-1% sodium dodecyl sulfate by a standard method
(12). The RNA to be used for PCR was precipitated twice
with 2 volumes of ethanol at -20°C overnight, dried under
vacuum, and resuspended in H20. The concentration of
rotavirus dsRNA from cell lysates was estimated by com-
parison with known amounts of dsRNA from purified virions
that were analyzed by polyacrylamide gel electrophoresis
(PAGE) and silver staining (16, 26).
HRV dsRNA was extracted from stool specimens with a
commercial glass powder preparation (RNAID or Geneclean
II; Bio 101, Inc., La Jolla, Calif.) by using a modification of
a published procedure (33). ISOGENE (Perkin-Elmer Cetus,
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Norwalk, Conn.) was also tested. Stool samples were sus-
pended in 50 mM Tris-hydrochloride (pH 7.5) at approxi-
mately 10 to 20% (wt/vol) or 10% (vol/vol) and were clarified
by centrifugation at 8,000 x g in a Beckman microcentrifuge
with a bowl rotor for 7 min. For primer sensitivity determi-
nations, purified virus particles were diluted serially in
clarified, rotavirus-negative stool supernatants, and the
dsRNA was extracted as described below. For some exper-
iments, 200 to 400 pl of the supernatant was extracted with
an equal volume of Freon and was clarified by centrifugation
at 8,000 x g for 5 min, and 200 to 400 RI of this supernatant
was mixed with sufficient 6 M guanidine thiocyanate to give
a final concentration of 3.4 M; for other experiments, 200 to
400 LI of the clarified stool supernatant was mixed directly
with guanidine thiocyanate (ultrapure grade; Boehringer
Mannheim) to give the same final concentration. RNAID (10
or 12 RI) was added to this mixture, and the sample was
vortexed and mixed on a Nutator rocker (Clay Adams
Division, Becton-Dickinson, Parsippany, N.J.) for 10 min at
room temperature. Each sample was then centrifuged for 30
s at 650 x g in a Beckman microcentrifuge, and the super-
natant was removed by aspiration with separate Pasteur
pipettes for each sample. The samples were then washed two
times with 400 RI of the RNAID kit wash buffer and
centrifuged at 850 x g. The supernatant was aspirated, and
the samples were washed once more with the same buffer
and were then finally centrifuged at 10,000 x g for 60 s. After
aspiration of the supematant, the samples were dried under
vacuum for 5 min, resuspended in 17.5 to 25 ,ul of deionized
H20, and incubated for 10 min at 65°C. The samples were
centrifuged at 10,000 x g for 30 s, and the supernatant was
transferred to microcentrifuge tubes (Lube Tube; Marsh
Co., Rochester, N.Y.). The pellet was reextracted with the
same volume of water (17.5 to 25 RI), and the combined
supernatants were stored at -20°C until they were used.
Immediately before use for PCR, the supernatants were
incubated at 56°C for 5 min and were then centrifuged at
10,000 x g for 15 s to pellet the residual RNAID from the
sample.
PCR. Our strategy to develop a PCR typing method for
gene 4 types was identical, in principle, to that used by
Gouvea and coworkers (12) for gene 9 (VP7) typing by PCR.
dsRNA was first reverse transcribed and amplified by PCR
(designated the first amplification step) with a primer pair
corresponding to gene 4 sequences that are highly conserved
among strains from VP4 genetic groups 1 to 4 (Fig. 1,
primers con 3 and con 2). Portions of the 876-bp product
dsDNAs were then amplified by PCR by using a cocktail of
primers that included the plus-sense consensus primer con 3
and the four minus-sense genetic group-specific primers
1T-1, 2T-1, 3T-1, and 4T-1. The nucleotide mismatch be-
tween the specific primers and the corresponding heterolo-
gous sequences ranged from 39 to 67%. Selection of specific
primers that gave products of different sizes permitted
identification of the VP4 genetic group by agarose gel
analysis. The use of a cocktail of primers has the added
advantage of identifying in one PCR the genetic group of any
HRV isolate from VP4 genetic groups 1 to 4.
For PCR experiments, dsRNA (approximately 50 to 250
ng per reaction) was prepared from rotavirus-infected cell
lysates or stool extracts. A two-amplification procedure was
usually used. Briefly, 1 to 5 RI of dsRNA was added to 0.5 ml
of low-bind microcentrifuge tubes containing 3.5 pl of di-
methyl sulfoxide (Sigma, St. Louis, Mo.) in a final volume of
8.5 pul, and the samples were mixed and denatured at 97°C
for 5 min in a heating block that contained mineral oil in its
wells. The samples were then cooled on ice for 5 min and
centrifuged at 10,000 x g for 10 s to remove the condensa-
tion from the walls of the tubes. A reverse transcription PCR
mixture (41.5 pA) containing 12 to 13.5 pI of H20, 16 PA of
deoxynucleoside triphosphate mixture (containing 1.25 mM
[each] dATP, dGTP, dCTP, and dTTP; Pharmacia-LKB,
Piscataway, N.J.), 5 ,u of 1Ox buffer II (100 mM Tris-
hydrochloride [pH 8.3], 500 mM KCI) (Perkin-Elmer Cetus),
3.5 to 5 pI of 25 mM MgCl2, 2 pl of primer (containing 25 pM
[each] con 3 and con 2), and 1.5 pI of RT reverse tran-
scriptase-Amplitaq or reverse transcriptase-Taq mixture
(containing 9 U of reverse transcriptase and 1.9 U of Taq or
Amplitaq) (Taq or Amplitaq worked equally well) was then
added to each denatured dsRNA sample tube (to give a final
reaction volume of 50 p.1). About 100 p.1 of mineral oil
(catalog no. M-3516; Sigma) was then added. The samples
were then mixed by gentle flicking, centrifuged at 10,000 x g
for 5 s, and subjected to one cycle of reverse transcrip-
tion (42°C, 30 min) and 30 cycles of PCR, both of which
were done in thermal cycler (Ericomp, Inc., San Diego,
Calif.). Each PCR cycle contained steps of 1 min at 94°C, 2
min at 50°C, and 2 min at 72°C. A cooling cycle was used to
bring the samples to 17°C at the completion of the experi-
ment.
More recently, we have used a separate reverse transcrip-
tion reaction in which the composition of the master mix was
the same as that described above, except that the final
volume was 49 [lI instead of 50 RI, Taq was left out, and
mineral oil was not added. In this case, after denaturation of
the RNA and addition of the master mix, the reverse
transcription reaction was incubated for 60 min at 42°C in a
circulating H20 bath. One microliter (1.9 U) of Taq was then
added; this was followed by the addition of 100 p.l of mineral
oil, and 30 cycles of PCR were carried out by using the same
steps described above.
For the typing reaction (second amplification), 0.5 to 5.0
pul of the first amplification product (5 pA was used if there
was no visible product and 0.5 p.l was used if there was a
large amount of product) was mixed with 45 p.1 of reaction
mixture in a final volume of 50 ,u1. When less than 5 ,ul of the
first amplification product was used, the volume was com-
pleted to 50 p.l with 10 mM Tris-hydrochloride (pH 8.3)-2.5
mM MgCl2. The components of the reaction mixture (per 45
pI) were 19.5 pl of water, 16 pA of deoxynucleoside triphos-
phate mixture, 5 p.1 of 1Ox buffer II, 3 pul of 25 mM MgCl2
(including the contribution of the first-amplification DNA
product; final MgCl2 concentration, 1.75 mM), 1 p.l of the
typing primer cocktail (containing 20 p.M [each] con 3, 1T-1,
2T-1, 3T-1, and 4T-1), and 0.5 pl (2.5 U) of Amplitaq. The
samples were overlaid with mineral oil, mixed by gentle
flicking, centrifuged, and subjected to 15 to 25 cycles of PCR
by using the same steps and cycles described above. The
samples were then analyzed by agarose gel electrophoresis.
Confirmation PCRs were carried out by using dsRNA as
the template and the same conditions as described above for
the first amplification of the typing reaction. The number of
PCR cycles varied from 25 to 30. Magnesium chloride
concentrations varied from 1.5 to 2.5 mM for the confirma-
tion primer pairs.
Agarose gel analysis. Agarose gel analysis of PCR products
was carried out by standard methods (11) by using 1.5 and
3.0% gels (and a 2:1 ratio of Nusieve GTG-Seaplaque [FMC
Bioproducts, Rockland, Maine]) for the first and second
PCR amplification products, respectively.
ELA serotyping. Strains were serotyped by using a MAb
EIA (31).
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TABLE 1. HRV strains used to test gene 4 PCR typing method
Straina VP7 VP4 VP4 geneticserotype serotype groupF
Wa 1 1A 1
KU 1 1A 1
YO 3 1A 1
P 3 1A 1
VA70 4 1A 1
HOCHI 4 1A 1
F45 9 1A 1
WI61 9 1A 1
DS1 2 1B 2
S2 2 1B 2
M37 1 2 3
1076 2 2 3
McN13 3 2 3
ST3 4 2 3
K8 1 3 4
AUl 3 ? 4(?)
69M 8 ? 5
a Only the nucleotide sequences of strains Wa, KU, P, VA70, DS1, RV5
(not used in this study), M37, 1076, McN13, ST3, K8, and 69M have been
completed (9, 14, 27, 29).b Adapted from reference 10.
c Adapted from reference 9.
Nucleotide sequence accession number. The GenBank ac-
cession number for the gene 4 sequence for HRV strain 1076
is M88480.
RESULTS
HRV strains used to test gene 4 typing method. To validate
the typing method for gene 4, we assembled a panel of
well-characterized strains (Table 1) from VP4 genetic groups
1 to 5. A direct correlation exists between genetic groups, as
determined by nucleotide sequence conservation (9) and
VP4 serotype (10), suggesting that methods for identifying
gene 4 types at the nucleic acid level are a valid proxy for
studying the gene 4 diversity of circulating HRV strains.
Gene 4 typing by PCR. Analysis of 17 strains was carried
out by two PCR amplifications. In the first, use of the
primers con 2 and con 3 yielded intense dsDNA products of
the predicted size (876 bp) for 14 of the 17 strains tested (Fig.
2). With strain WI61 (Fig. 2, lane 8), the absence of a product
band was probably an artifact caused by extraneous mate-
rial, perhaps cellular nucleic acids (after PAGE and silver
staining, this preparation had a very high background) in the
RNA preparation. Likewise, the high-molecular-weight
bands observed in strain W161 and several other products
(especially products from strains Wa and S2; Fig. 2, lanes 1
and 10, respectively) may be artifacts of amplification of
complex nucleic acids from cells, since they were not primer
specific (also see Fig. 4) and were not observed after
amplification of rotavirus RNAs extracted from stools. We
confirmed that W161 dsRNA can be efficiently amplified with
con 3 and con 2 by repeating this experiment with RNA from
a partially purified virus preparation (data not shown). We
also demonstrated, using other dsRNA preparations, that
strain 1076 (Fig. 2, lane 12) can be reproducibly amplified to
produce an 876-bp dsDNA, although at a somewhat lower
yield (data not shown).
M 1 2 3 4 5 6 7 8 9 1011 121314151617
FIG. 2. Reverse transcription and PCR amplification (first ampli-
fication) of rotavirus dsRNAs with consensus primers con 3 and con
2. dsRNAs were prepared from lysates of infected cells by phenol-
chloroform extraction and were amplified as described in Materials
and Methods. Products were analyzed by agarose gel electrophore-
sis and ethidium bromide staining. Markers (lane M) are (X174 and
HaeIII restriction fragments. Products were amplified from HRV
strains possessing gene 4 type 1 (lane 1, Wa viral dsRNA; lane 2,
KU; lane 3, YO; lane 4, P; lane 5, VA70; lane 6, HOCHI; lane 7,
F45; lane 8, W161), type 2 (lane 9, DS1; lane 10, S2), type 3 (lane 11,
M37; lane 12, 1076; lane 13, ST3; lane 14, McN13), type 4 (lane 15,
K8), and type 5 (lane 17, 69M). The sequence of strain AUl gene 4
(lane 16) has not been published. Numbers on the right are ex-
pressed in base pairs.
The nature of the nonspecific but discrete products that we
and others have observed at various intensities from exper-
iment to experiment (Fig. 2 and 3) (22) has not been
characterized, but it probably results from mispriming
events during amplification of complex nucleic acids (4).
These products do not interfere with gene 4 typing.
When portions of the first amplification products were
subjected to gene 4 typing PCR (Fig. 3), we observed that
only the eight reactions primed with dsDNA derived from
HRV strains from VP4 genetic group 1 produced a dsDNA
product of about 345 bp (Fig. 3, lanes 1 to 8), the expected
size of the product of con 3 and the genetic group 1-specific
primer 1T-1 (Fig. 1). No significant products indicative of
FIG. 3. Typing by PCR of gene 4 from HRV strains. Portions of
the products from reactions used to generate Fig. 2 were amplified
by PCR by using a cocktail of consensus primer con 3 and primers
1T-1 to 4T-1 and were analyzed by agarose gel electrophoresis and
ethidium bromide staining. The lane designations are the same as
those in Fig. 2. Because the 4X174 (+X) markers were very faint,
the positions of fragments of relevant sizes (603 to 194 bp) are
indicated on the left. The relevant fragments of the pBR restriction
fragments are (PBR lane, largest to smallest fragments) 622, 527,
404, 309, and 242 plus 238 bp, respectively.
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FIG. 4. Confirmation of HRV gene 4 types by PCR. Rotavirus dsRNAs were reverse transcribed and amplified by PCR by using a gene
4 type 1-specific primer pair (A), a type 2-specific primer pair (B), a type 3-specific primer pair (C), or a type 4-specific primer pair (D). The
strains that were amplified and the lanes in which they tested are the same as those in Fig. 2.
hybridization of group 2-, 3-, or 4-specific primers to the
dsDNAs from strains that possess genetic group 1 gene 4's
were observed (i.e., products of 267, 391, or 483 bp).
Likewise, only reactions primed with dsDNAs from strains
that possess gene 4's from genetic group 2, 3, or 4 produced
products of about 483 bp (genetic group 2; Fig. 3, lanes 9 and
10), 267 bp (group 3; Fig. 3, lanes 11 to 14), and 391 bp (group
4; Fig. 3, lane 15), which are the predicted lengths of the
products of amplification of these DNAs with con 3 and the
group-specific primers 2T-1, 3T-1, and 4T-1, respectively.
The typing band for strain WI61 (Fig. 3, lane 8) was not
visible, while the band for strain 1076 (Fig. 3, lane 12) was
faintly visible. We subsequently demonstrated, using other
RNA preparations, that both can be reliably typed (data not
shown). Strain AUl (Fig. 3, lane 16) was included in this
experiment because the genes of this strain appear to be
closely related to those of strain K8 (i.e., as a possible
second member of VP4 genetic group 4), as determined by
hybridization (5, 24). Strain AUl gave a very weak band of
391 bp (comigrating with the product of strain K8) and
several nonspecific bands, suggesting that it cannot be
reliably typed. The reason that we cannot amplify strain
AUl efficiently will not be known until the AUl gene 4 is
sequenced. In the meantime, we are trying to obtain alter-
nate K8-like and AUl-like isolates to determine whether this
result is peculiar to the AUl isolate in our laboratory.
The failure of strain 69M to give a detectable product (Fig.
3, lane 17) was not surprising, since it possesses a unique
gene 4 whose sequence was not published when we carried
out this study. After its sequence was published, we de-
signed two typing primers for 69M and have shown that
(when they were used in a primer cocktail with con 3 and
iT-1 to 4T-1) they produce 583- and 660-bp products from
69M DNA after the first amplification but not from compa-
rable DNAs produced from VP4 genetic group 1 to 4 strains
(data not shown). Taken together, these results suggest that
the VP4 genetic groups of 16 of 16 well-characterized (ex-
cluding strain AU1) prototype HRV strains can be reliably
identified on the basis of the size of the PCR products
produced during the second (typing) PCR amplification.
PCR confirmation of gene 4 typing. Additional genetic
group-specific primer pairs (one plus-sense and one minus-
sense primer for each pair) were selected for each genetic
group for cases in which confirmation of a typing reaction
was needed. Since some of these primer pairs interfere with
each other when they are used as a cocktail, they were used
separately in PCRs, starting with HRV dsRNA as a template
(i.e., confirmation is a one-step reverse transcription and
PCR amplification procedure). To summarize these results,
primer pairs iC-1 and 1C-2, 2C-1 and 2C-2, 3C-1 and 3C-2,
and 4C-1 and 4C-2 (specific for genetic groups 1, 2, 3, and 4,
respectively) specifically reverse transcribe and amplify
dsRNA of HRV strains from VP4 genetic groups 1 to 4,
respectively, to yield 180-, 504-, 206-, and 261-bp products
(Fig. 4, A to D, respectively). Although strain WI61 did not
produce a specific product in the experiment (Fig. 4A, lane
8), we confirmed that primer pairs iC-1 and 1C-2 can
specifically reverse transcribe and amplify dsRNA from
partially purified WI61 virus particles (data not shown).
Gene 4 typing of HRV in stool samples. To study the
diversity of gene 4 types in circulating strains of HRV, we
first developed a method to improve the extraction of
dsRNA from stool samples. Recent experience with our
previous methods demonstrated that some specimens ampli-
fied poorly; we believed that this was due to inhibitors of
reverse transcriptase that were present in the stool samples
(11). A recent report (33) described the use of glass powder
for RNA extraction and suggested that inhibitors in stool
could be reduced or eliminated by its use (33). Several types
of glass powder, ISOGENE, GENECLEAN II, and
RNAID, are commercially available (33, 34). Although our
preliminary results showed that all three glass powders could
extract dsRNA from stool samples, we chose to analyze
RNAID in detail because of the better qualitative results
obtained with that glass powder. The RNAID method was
chosen over the hydroxyapatite method reported previously
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D
FIG. 5. Sensitivity of the two-amplification PCR for gene 4 typing. Tenfold serial dilutions of purified virus particles (1011 to 101 particles)
from strains Wa (gene 4 type 1), DS1 (type 2), M37 (type 3), and K8 (type 4) were carried out in clarified stool suspensions; and the dsRNA
of each virus particle was extracted with RNAID glass powder. One-tenth of each sample was reverse transcribed and amplified by PCR with
consensus primers con 3 and con 2, and 2.5 ,l of each sample was subjected to typing by PCR as described in the legend to Fig. 3. (A) Gene
4 typing of the DNA product from Wa virus dilutions (lanes 1 to 10 correspond to the analysis of the dsRNA from 109 to 100 virus particles,
respectively, assuming 100% recovery). (B) Gene 4 typing of DNA from DS1 virus dilutions (lanes 1 to 10 correspond to the analysis of the
dsRNA from 1010 to 101 virus particles, respectively). (C) Gene 4 typing of DNA from M37 virus dilutions (lanes 1 to 10 correspond to the
analysis of the dsRNA from 109 to 100 virus particles, respectively). (D) Gene 4 typing of DNA from K8 virus dilutions (lanes 1 to 10
correspond to the analysis of the dsRNA from 109 to 100 virus particles, respectively). The molecular masses of the pBR restriction fragments
(lane M) are given in lane PBR of Fig. 3.
(11) because phenol-chloroform extraction was not neces-
sary and it was more sensitive. Using RNAID with the
two-step gene 4 typing method, we could detect dsRNAs
from as few as 1,000 Wa (VP4-genetic group 1), 1,000 DS1
(group 2), 10 M37 (group 3), or 1,000 K8 (group 4) virus
particles pipetted into a stool specimen (Fig. 5).
To determine whether the stool extraction and gene 4
typing methods had utility for diverse strains of circulating
HRV, we analyzed several sets of samples from the United
States, Mexico, Costa Rica, and Venezuela. Of the eight
VP7 serotype 2 samples from Costa Rica (Fig. 6) that were
reverse transcribed and amplified with con 3 and con 2 (Fig.
6A, lanes 6 to 13), seven had visible products (Fig. 6A, lanes
6 to 10 and 12) (although they are not visible in Fig. 6A, a
product was faintly visible in lane 11 of the original photo-
graph [data not shown]). Products of 876 bp were found in all
four positive control dsRNAs from VP4 genetic groups 1 to
4 (Fig. 6A, lanes 1 to 4), but not in a known rotavirus-
negative stool sample (Fig. 6A, lane 5). When portions of
these dsDNAs were subjected to gene 4 typing by PCR (Fig.
6B, lanes 6 to 13), seven of the eight Costa Rican samples
produced dsDNA products (Fig. 6B, lanes 6 to 10, 12)
(although they are not visible in Fig. 6B, a product was
faintly visible in lane 11 of the original photograph [data not
shown]), all of which comigrated with the genetic group
2-positive control (Fig. 6B, lane 2; 483-bp dsDNA). Of the
eight samples that were positive for genetic group 2 in the
typing reaction, five were confirmed by the production of a
504-bp product (Fig. 6C, lanes 7 to 10 and 12), and one
additional genetic group 2-positive sample was obtained in a
repeat experiment by using confirmation primers 2C-1 and
2C-2.
We also validated the method described here for stool
samples containing rotaviruses with VP7 serotype 1 speci-
ficity (from ill children in the United States) and for speci-
mens containing rotaviruses with VP7 serotype 1 or 4
specificity (from newborn infants in a Venezuelan hospital
neonatal ward) (17) (gene 4 typing results for U.S. children
and Venezuelan infants are shown in Fig. 7 and 8, respec-
tively). In total (Table 2), we analyzed 50 samples, and 47
were positive by PCR. We found that, with one exception,
strains with VP7 serotype 1 specificity were from VP4
genetic group 1, whereas all of the VP7 serotype 2 isolates
were from genetic group 2. The lone exception to this
pattern, excluding isolates from infants in neonatal wards
(i.e., the Venezuelan isolates), was a VP7 serotype 1 isolate
from Mexico, which contained a genetic group 3 gene 4.
Among the 14 known (eight VP7 serotype 1 and 6 VP7
serotype 4) strains from Venezuela that caused asympto-
matic infections, all but 1 (which was negative by PCR) were
from VP4 genetic group 3, which is in agreement with the
results of a hybridization study previously conducted with
these isolates (17). The few samples (3 of 50) that were
antigen positive but negative by PCR (using at least two
different pairs of primers) were not analyzed further.
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FIG. 6. PCR typing and confirmation of VP7 serotype 2 samples
from Costa Rica. (A) Samples were reverse transcribed and ampli-
fied by PCR with HRV consensus primers con 3 and con 2; lanes 1
to 4, 876-bp DNAs generated from HRV strains possessing gene 4
types 1 (Wa), 2 (DS1), 3 (M37), and 4 (K8), respectively; lane 5,
products amplified from a stool specimen negative for rotavirus;
lanes 6 to 13, 876-bp products amplified from stool samples contain-
ing VP7 serotype 2 HRV strains from Costa Rica. (B) Portions of the
products shown in panel A. The samples in lanes 1 to 13 were
amplified by PCR by using the cocktail of gene 4 typing primers
described in the legend to Fig. 3. The sizes of typing bands for gene
4 types 1, 2, 3, and 4 were 345, 483, 267, and 391 bp, respectively.
(C) The dsRNAs used to generate the products shown in panel A.
The samples in lanes 1 to 13 were reverse transcribed and amplified
with a primer pair specific for gene 4 type 2, and the products were
analyzed as described in the legend to Fig. 2. The extra marker band
(fifth band from the top) in the iX174 marker (lane M) is a 500-bp
dsDNA that was produced by using the control primers and tem-
plate from the Perkin-Elmer Cetus PCR kit.
DISCUSSION
In this report we described a PCR method for identifying
the gene 4 types of HRV strains. In the absence of MAbs
that would permit discrimination of the known VP4 types by
EIA, this method, along with a recently published hybrid-
ization technique for the same purpose (17), serves as a
proxy for the determination of the VP4 genetic group of
HRV strains directly from stool samples. To increase the
FIG. 7. Typing by PCR of gene 4 from a group of predominantly
VP7 serotype 1 strains. Samples were extracted with RNAID glass
powder, reverse transcribed, and amplified by PCR as described in
the legend to Fig. 5. Portions of the products were subjected to
typing by PCR as described in the legend to Fig. 5. Lanes 1 to 4,
positive controls; lane 5, negative control; lanes 6 to 14, gene 4
typing products for a group of rotavirus samples from the United
States.
sensitivity of the reaction (1, 12), we used a two-step (nested
priming) method for gene 4 typing in which a primer pair
corresponding to highly conserved regions was used to
generate an 876-bp dsDNA from the 5'-terminal third of gene
4 by reverse transcription and PCR amplification of dsRNA
(first amplification). The DNA was subsequently used as a
template in the gene 4 typing PCR (second amplification) by
using a cocktail of one plus-sense consensus primer and four
(one for each gene 4 type) genetic group-specific minus-
sense primers selected from sequences of gene 4 lying within
the 876-bp region. It should be noted that, although false-
positive results were not observed in the experiments de-
scribed here, use of two amplification methods increases the
chance of cross-contamination during the manipulation of
samples, and therefore, appropriate negative controls should
be included as monitors for this problem.
FIG. 8. Typing by PCR of gene 4 from a group of HRV strains of
VP7 serotypes 1 and 4 that caused asymptomatic infections. Sam-
ples were extracted with RNAID glass powder, reverse transcribed,
and amplified by PCR as described in the legend to Fig. 5. Portions
of the products were subjected to gene 4 typing by PCR as described
in the legend to Fig. 5. Lanes 1 to 4, positive controls; lanes 5 to 18,
products for a group of rotavirus samples from Venezuela deter-
mined by PCR typing; lane 19, negative control.
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TABLE 2. Summary of HRV gene 4 typing
Gene 4 No. of samples with No. of
PCR the following VP4 VP7
Sample typing genetic group: serotype:
origin
No. of No. of
samples samples 1 2 3 4 Mixed 1 2 3 4
tested positive
United States 19 18 16 1 0 0 1 7 1 0 0
Venezuela 14a 13 0 0 13 0 0 8 0 0 6
Mexico 9 9 2 6 1 0 0 3 6 0 0
Costa Rica 8 7 0 7 0 0 0 0 8 0 0
Total 50 47
a VP7 serotypes were determined by EIA and a serotype-specific hybrid-
ization method (6). The samples were also shown previously to have M37-like
gene 4's (17).
The regions from which the typing primers were selected
represent the most variable sequences of gene 4 among
strains from different genetic groups, as demonstrated by
comparative nucleotide sequencing and the predicted amino
acid sequence (9). Evidence that this region of VP4 (the VP8
cleavage fragment) contains the antigenic sites involved in
delineating VP4 serotypes has also been presented (10). As
for the hypervariable regions of genes 7 to 9, which are
responsible for delineating VP7 serotypes (15), the compa-
rable regions of gene 4 are highly conserved among HRV
strains in the same VP4 genetic group and, thus, are well-
suited for selecting group-specific PCR primers.
The method described here is highly specific, in that the
genetic groups of 16 well-characterized HRV strains could
be reliably identified. Likewise, the sensitivity of the method
is very high. With the typing primers for which we had
sensitivity data, we could obtain a positive typing reaction
with the dsRNA from as few as 10 to 1,000 virus particles
(this sensitivity is 500 to 50,000 times more sensitive than
that obtained by using ROTACLONE, a commercial EIA,
and about 200 to 20,000 times greater than that of a recently
reported hybridization method for gene 4 typing [17]). Thus,
PCR typing may be advantageous in samples with < 108 virus
particles per ml of stool extract.
Gene 4 typing offers several other important benefits.
First, on the basis of the observation that all members of a
VP4 genetic group (from nucleotide and deduced amino acid
sequence conservation) can be classified into the same VP4
antigenic group (10) and in the absence of immunologic
methods (either MAb- or polyclonal antibody-based tests) to
study the antigenic diversity of VP4, gene 4 typing by PCR
and a recently reported hybridization method for the same
purpose (17) serve as valid proxy methods to assess VP4
diversity. Although the VP4 proteins of genetic group 1 to 4
strains can be distinguished by cross-neutralization tests
with antisera to VP4 or VP8 polypeptides that are expressed
(10, 18), these tests are too cumbersome for studying VP4
diversity in field isolates, and MAbs that are able to distin-
guish the known VP4 antigenic types have yet to be isolated.
Second, in conjunction with recently described PCR (12),
hybridization (17) and EIA (31) methods for use in the
identification of VP7 serotype specificity, gene 4 typing will
permit us to more fully characterize the diversity of both
HRV neutralization antigens before MAbs with new VP4
and VP7 specificities become available.
Our initial results indicate that HRV isolates from two
epidemiologically important VP7 serotypes (serotypes 1 and
2) from several parts of the world possess almost exclusively
gene 4 types 1 and 2. This finding was not unexpected, since
gene 4 types 1 and 2 have been identified (by nucleotide
sequencing) only in prototype strains with VP7 serotype 1, 3,
and 4 (type 1) and VP7 serotype 2 (type 2) specificities. In
another recent study in which a hybridization method was
used, type 1 gene 4 was identified in strains with VP7
serotype 3, 4, and 9 specificities (>50% of the total number
of samples with typeable gene 4's) and type 2 gene 4 was
identified in strains with VP7 serotype 2 specificity (about
20% of the total) (28). Taken together, these results suggest
that strains with VP4 serotype 1A and 1B specificities (type
1 and 2 gene 4's) are predominant strains in many areas of
the world. A single isolate with a type 3 gene 4 and VP7
serotype 1 specificity was identified in an asymptomatic
Mexican infant who excreted rotavirus. Such strains (fre-
quently designated neonatal or asymptomatic rotaviruses)
have been isolated almost exclusively from newborn infants
in neonatal wards, are shed asymptomatically, can belong to
VP7 serotypes 1 to 4, and share a highly conserved gene 4
that has been postulated to account for their avirulent
phenotype (9). All other isolates containing type 3 gene 4's
identified in this study were from infants in neonatal wards
(Table 2). It will be interesting to determine the frequency
with which these strains occur in subjects with symptomatic
infections, and in this regard, several isolates with type 3
gene 4's have recently been identified in neonates or older
infants with gastroenteritis (28). The other two gene 4 types
(types 4 and 5) occur in strains that have been isolated only
rarely (2, 21, 29). Gene 4 typing will permit us to better
assess the frequency and distribution of gene 4 types and to
determine whether they occur in strains with various VP7
serotype specificities. In a recent study (28), strains with a
type 5 gene 4 and VP7 serotype 1, 3, 6, and 8 specificities
have been identified at a low frequency (<10% of total typed
samples) in HRV isolates from several countries, suggesting
that reassortment may contribute to antigenic diversity in
these strains, as observed previously for rotaviruses with
VP4 serotype 1A and 2 specificities (10).
The need for a dual serotyping system for II4RV VP4 and
VP7 was suggested several years ago (13). Recent studies on
the genetic and antigenic diversities of HRV VP4 have
confirmed the need for a VP4 classification system (10, 18),
but the several different terminologies which have arisen to
describe the genetic and antigenic specificities attributed to
VP4 and VP7 (9, 10, 30) have resulted in some confusion in
this field. We support the adoption of the proposed binary
nomenclature system for rotavirus serotyping. The system
designates the antigenic specificities attributed to VP7 as G
types and those attributed to VP4 as P types (30).
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